Mouth

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

Retrieved on: 
Tuesday, September 12, 2023
Cancer, Head, SOC, The Christ Hospital, Patient, Lymph, Throat, Therapy, Mouth, Cholangiocarcinoma, Pharmaceutical industry

BASKING RIDGE, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) --  Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced treatment of the first patient in the head and neck squamous cell carcinoma cohort of the BOLSTER trial, by Dr. Alexander N. Starodub, a principal investigator of the study, at The Christ Hospital in Cincinnati, Ohio.

Key Points: 
  • The BOLSTER trial is a basket trial being conducted at approximately 40 sites in North America, Europe, and Asia-Pacific.
  • Total trial enrollment of 120 patients is expected to be completed in the second half of 2024.
  • “We are excited to announce treatment of the first patient in the second-line head and neck squamous cell carcinoma cohort of the BOLSTER trial.
  • “Now that the first patient in BOLSTER has been treated, we expect an uptake in enrollment in the coming quarters.

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Retrieved on: 
Monday, September 11, 2023
Hepatitis, Mouth, Ascending cholangitis, Hepatology, Liver disease, PBC, Biotechnology, Atopic dermatitis, US, Primary biliary cholangitis, Patient, Liver, Cheek, Alcoholic liver disease, IND, Chronic kidney disease, Skin, Pharmaceutical industry, Hillstream loach

BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancer announces an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved IND. AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis or “uncontrollable itching”. The Company intends to first seek approval in an orphan disease for the treatment of moderate to severe cholestatic pruritis in patients with primary biliary cholangitis (PBC), a rare form of liver disease with no known cure in which more than 70% of patients suffer from chronic pruritis.

Key Points: 
  • AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis or “uncontrollable itching”.
  • When the itch circuitry is imbalanced in diseased conditions, pharmacological intervention can help suppress this phenomenon which occurs in patients suffering from chronic pruritis.
  • Chronic pruritis is significant in liver diseases as well as chronic kidney diseases, hemodialysis and atopic dermatitis.
  • “This exclusive option allows the company to bring a clinical-stage asset into the organization as we shift into a patient-focused biotechnology organization.

GET CLOSER TO THE HARVEST MOON AND CELEBRATE WITH VISTAJET

Retrieved on: 
Thursday, September 7, 2023
Reunion, VistaJet, Magic, Noise, Fortnum, Friends, Culture, Vista, Moon rabbit, Bellini, Michelin, Fortnum & Mason, Mid-Autumn Festival, Chuseok, Movement, Herbal, Bergamot, Restaurant, Citrus, Tea, Atti, Family, Mouth, Rose, Hong, Entertainment, Film industry, Tourism

As many across the region mark the harvest moon with traditional festivals, VistaJet is creating memorable moments as our clients admire the moon 45,000 feet up in the sky.

Key Points: 
  • As many across the region mark the harvest moon with traditional festivals, VistaJet is creating memorable moments as our clients admire the moon 45,000 feet up in the sky.
  • Throughout September, VistaJet invites Members to discover its Full Moon on Board experience, curated by world-renowned event-planners Sharky and George.
  • VistaJet Members will be able to indulge their loved ones in culinary sensations on board their flight, prepared by award-winning chefs and restaurants.
  • They can taste mooncakes custom-made for VistaJet with premium Chinese tea or pair their favorite mooncake flavors with sparkling tea mocktails using unique recipes created only for VistaJet.

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, MSD, Vaccination, Chills, Public, Anaphylaxis, Arthralgia, Rash, Committee, Milk, Plasma, Risk, Committee for Medicinal Products for Human Use, European, EVD, NYSE, Saliva, Fatigue, Disease, Antigen, Pregnancy, Diarrhea, Urine, Somnolence, MRK, Appetite, UNICEF, Merck & Co., Myalgia, Vomiting, Child, Immunodeficiency, Headache, Ebola, Irritability, Mouth, Safety, Screaming, Fever, Civil service commission, Arthritis, History, Abdominal pain, Hyperhidrosis, IG, Allergy, Dizziness, Blood, European Medicines Agency, European Commission, Breast milk, CHMP, Infection, European Directive on Traditional Herbal Medicinal Products, RNA, Nausea, EC, Vaccine, Birth control, Merck, EU, Ebolavirus, Marburgvirus

The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.

Key Points: 
  • The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.
  • “Ebola virus disease is severe and potentially life-threatening for both children and adults.
  • INDICATIONS AND USAGE IN THE U.S.
    ERVEBO® is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
  • Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.

Mackmyra creates whisky history with Sweden's first 20-year-old single malt

Retrieved on: 
Wednesday, September 13, 2023
Ageing, Honey, Glass, Vanilla, History, Mouth, Citrus, Beer, Systembolaget, Mackmyra Whisky

GÄVLE, Sweden, Sept. 13, 2023 /PRNewswire/ -- Mackmyra Svensk Whisky proudly presents the launch of Sweden's first 20-year-old single malt whisky.

Key Points: 
  • GÄVLE, Sweden, Sept. 13, 2023 /PRNewswire/ -- Mackmyra Svensk Whisky proudly presents the launch of Sweden's first 20-year-old single malt whisky.
  • This unique whisky has been carefully aged for a full twenty years in ex-bourbon casks, 50 meters underground in the Bodås mine.
  • Mackmyra has always been a pioneer in exploring and developing Swedish flavors in the whisky world.
  • This 20-year-old single malt whisky is no exception.

New Smokey Bear PSAs Encourage Americans to Channel the "Smokey Within" and Help Prevent Unwanted, Human-Caused Wildfires

Retrieved on: 
Wednesday, September 13, 2023
Smokey Bear, Council, Human, Partnership, Mouth, PSAS, Parent, Wildfire, Ad Council, U.S. Forest Service airtanker scandal, Fire, Emotion, Forest, National Association of State Foresters, OOH, United States Forest Service, Camping, Radio, National Association, FCB, Research, Empowerment, Forestry, Tourism, Smoky

"What better way to continue his legacy and illustrate the power we all have in preventing wildfires than by showing the public how Smokey is within all of us."

Key Points: 
  • "What better way to continue his legacy and illustrate the power we all have in preventing wildfires than by showing the public how Smokey is within all of us."
  • For nearly 80 years, Smokey has been the nation's favorite bear educating the public on how to prevent human caused wildfires and his message is as important now as ever.
  • Developed by FCB, the creative agency behind Smokey Bear since he was first introduced to the world in 1944, the new "Smokey is Within" campaign highlights everyday people who channel their inner Smokey Bear in moments of need.
  • "'Smokey Bear lives within us all' is a powerful message to remind everyone that we all play a role in wildfire prevention.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Monday, September 11, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Monday, September 11, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Friday, September 8, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 8, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Align Technology Introduces the Invisalign® Palatal Expander System to Address Skeletal Expansion in Growing Patients, Including Teenage Patients Which Represent the Majority of Orthodontic Case Starts Globally

Retrieved on: 
Wednesday, September 6, 2023
Health, Dental, Medical Devices, Align Technology, Anatomy, Maxilla, Food, 3D, Multimedia, Research, Movement, Trial of the century, Pain, Patient, Child, Oral hygiene, IDE, Dentition, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mouth, Splint (medicine), Dentistry, Align

Invisalign Palatal Expanders are intended for use in rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed, or permanent dentition during treatment of growing patients.

Key Points: 
  • Invisalign Palatal Expanders are intended for use in rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed, or permanent dentition during treatment of growing patients.
  • View the full release here: https://www.businesswire.com/news/home/20230906445005/en/
    Dr. Sandra Tai’s patient independently inserting Invisalign® Palatal Expander.
  • A palatal expansion treatment plan and device design are then developed using Align’s proprietary AI-driven orthodontic software.
  • Based on data from a multi-site US Early Feasibility Investigational Device Exemption (IDE) clinical study (n=29 subjects, ages 7-10 years) of expansion treatment with Invisalign® Palatal Expanders.